267 related articles for article (PubMed ID: 32379804)
1. Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
Medeiros CMP; Moreira EUM; Pires CV; Torres LM; Guimarães LFF; Alves JRS; Lima BAS; Fontes CJF; Costa HL; Brito CFA; Sousa TN; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
PLoS One; 2020; 15(5):e0232786. PubMed ID: 32379804
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to
Alves JRS; de Araújo FF; Pires CV; Teixeira-Carvalho A; Lima BAS; Torres LM; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
Front Immunol; 2021; 12():704653. PubMed ID: 34675915
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
[TBL] [Abstract][Full Text] [Related]
4. The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.
Kano FS; Souza-Silva FA; Torres LM; Lima BA; Sousa TN; Alves JR; Rocha RS; Fontes CJ; Sanchez BA; Adams JH; Brito CF; Pires DE; Ascher DB; Sell AM; Carvalho LH
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005177. PubMed ID: 27959918
[TBL] [Abstract][Full Text] [Related]
5. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
George MT; Schloegel JL; Ntumngia FB; Barnes SJ; King CL; Casey JL; Foley M; Adams JH
mSphere; 2019 May; 4(3):. PubMed ID: 31092602
[TBL] [Abstract][Full Text] [Related]
6. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.
Ntumngia FB; Adams JH
Clin Vaccine Immunol; 2012 Jan; 19(1):30-6. PubMed ID: 22116684
[TBL] [Abstract][Full Text] [Related]
7. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.
Wongkidakarn S; McHenry AM; Sattabongkot J; Adams JH; Chootong P
PLoS One; 2016; 11(5):e0154577. PubMed ID: 27145131
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
[TBL] [Abstract][Full Text] [Related]
9. Identification and Characterization of Functional Human Monoclonal Antibodies to
Carias LL; Dechavanne S; Nicolete VC; Sreng S; Suon S; Amaratunga C; Fairhurst RM; Dechavanne C; Barnes S; Witkowski B; Popovici J; Roesch C; Chen E; Ferreira MU; Tolia NH; Adams JH; King CL
J Immunol; 2019 May; 202(9):2648-2660. PubMed ID: 30944159
[No Abstract] [Full Text] [Related]
10. Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.
Chootong P; Panichakul T; Permmongkol C; Barnes SJ; Udomsangpetch R; Adams JH
PLoS One; 2012; 7(4):e35769. PubMed ID: 22558221
[TBL] [Abstract][Full Text] [Related]
11. The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand.
Chootong P; McHenry AM; Ntumngia FB; Sattabongkot J; Adams JH
Parasitol Int; 2014 Dec; 63(6):858-64. PubMed ID: 25108177
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design.
Chen E; Salinas ND; Ntumngia FB; Adams JH; Tolia NH
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003644. PubMed ID: 25793371
[TBL] [Abstract][Full Text] [Related]
13. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.
Ntumngia FB; King CL; Adams JH
Int J Parasitol; 2012 Nov; 42(12):1055-62. PubMed ID: 23068913
[TBL] [Abstract][Full Text] [Related]
14. Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
Nicolete VC; Frischmann S; Barbosa S; King CL; Ferreira MU
J Infect Dis; 2016 Nov; 214(10):1539-1546. PubMed ID: 27578850
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to a new member of the DBL family (EBP2) after a brief Plasmodium vivax exposure.
Lima BAS; Fernandes GM; Torres LM; Pires CV; Alves JRS; Moreira-Nascimento SL; Nascimento MFA; Afonso SL; Costa HL; Cerávolo IP; Sousa TN; Soares IS; Ntumngia FB; Adams JH; Carvalho LH; Kano FS
PLoS Negl Trop Dis; 2022 Jun; 16(6):e0010493. PubMed ID: 35714097
[TBL] [Abstract][Full Text] [Related]
16. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.
King CL; Michon P; Shakri AR; Marcotty A; Stanisic D; Zimmerman PA; Cole-Tobian JL; Mueller I; Chitnis CE
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8363-8. PubMed ID: 18523022
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.
Chen E; Salinas ND; Huang Y; Ntumngia F; Plasencia MD; Gross ML; Adams JH; Tolia NH
Proc Natl Acad Sci U S A; 2016 May; 113(22):6277-82. PubMed ID: 27194724
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
Urusova D; Carias L; Huang Y; Nicolete VC; Popovici J; Roesch C; Salinas ND; Dechavanne S; Witkowski B; Ferreira MU; Adams JH; Gross ML; King CL; Tolia NH
Nat Microbiol; 2019 Sep; 4(9):1486-1496. PubMed ID: 31133752
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria.
He WQ; Shakri AR; Bhardwaj R; França CT; Stanisic DI; Healer J; Kiniboro B; Robinson LJ; Guillotte-Blisnick M; Huon C; Siba P; Cowman A; King CL; Tham WH; Chitnis CE; Mueller I
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0006987. PubMed ID: 30768655
[TBL] [Abstract][Full Text] [Related]
20. An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.
Ntumngia FB; Pires CV; Barnes SJ; George MT; Thomson-Luque R; Kano FS; Alves JRS; Urusova D; Pereira DB; Tolia NH; King CL; Carvalho LH; Adams JH
Sci Rep; 2017 Oct; 7(1):13779. PubMed ID: 29062081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
